abstract |
The present invention relates to a dosage and administration regimen of anti-C5 antibodies, particularly of the anti-C5 antibody Crovalimab, for use in a method of treating or preventing C5-related disease in a subject, including paroxysmal nocturnal hemoglobinuria (PNH). The dosage and treatment regimen of the present invention include the administration of an anti-C5 antibody, preferably of the anti-C5 antibody Crovalimab, with loading doses followed by the administration of (a) maintenance dose(s) of the anti-C5 antibody to the subject, wherein the initial administered loading dose is intravenously given to the subject and the remaining loading and maintenance doses are subcutaneously administered in a lower dosage as the intravenously administered loading dose. |